Results 11 to 20 of about 112,514 (282)

Peroxiredoxin 1-Toll-like receptor 4-p65 axis inhibits receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation [PDF]

iScience
Summary: Peroxiredoxin 1 (PRDX1), an intracellular antioxidant enzyme, has emerged as a regulator of inflammatory responses via Toll-like receptor 4 (TLR4) signaling.
Jisu Park, Sanggil Kim, Hye-Yeon Jung, Eun Hwan Bae, Minhye Shin, Jae-Il Park, So-Young Choi, Sun-Ju Yi, Kyunghwan Kim   +8 more
doaj   +2 more sources

Receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in gingival crevicular fluid

Dental Research Journal, 2012
Background: Osteoclastogenesis is coordinated by the interaction of three members of the tumor necrosis factor (TNF) superfamily: Osteoprotegerin (OPG)/receptor activator of nuclear factor kappa B ligand (RANKL)/receptor activator of nuclear factor kappa
Fatemeh Sarlati, Mandana Sattari, Shilan Razzaghi, Malihe Nasiri   +3 more
doaj   +3 more sources

Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma. [PDF]

Ann Transl Med, 2016
Receptor activator of nuclear factor kappa-B ligand (RANKL) is a member of the tumor necrosis factor receptor superfamily and is considered the most important factor for osteoclastogenesis. RANKL is encoded by a gene, which is found at chromosome 13q14 and is expressed mainly by osteocytes, activated T-cells and bone marrow stromal cells.
Panagiotidis I, Christoulas D, Terpos E.
europepmc   +5 more sources

Expression Profiling of Receptor-Activator of Nuclear Factor-Kappa B Ligand in Soft Tissue Tumors

The Tohoku Journal of Experimental Medicine, 2019
Bone and soft tissue tumors are derived from mesenchymal cells, and they are hard to treat. Receptor-activator of nuclear factor-kappa B ligand (RANKL) is an essential cytokine for osteoclast differentiation and activation and is expressed on the surface of osteoblasts or stromal cells. In this study, to explore the potential of denosumab treatment for
Tetsuro, Yamagishi, Hiroyuki, Kawashima, Akira, Ogose, Takashi, Ariizumi, Naoki, Oike, Taro, Sasaki, Hiroshi, Hatano, Riuko, Ohashi, Hajime, Umezu, Yoichi, Ajioka, Naoto, Endo   +10 more
openaire   +5 more sources

Receptor activator of nuclear factor kappa-B gene polymorphisms in Iranian periodontitis and peri-implantitis patients. [PDF]

J Periodontal Implant Sci, 2014
Peri-implantitis and periodontitis are inflammatory and infectious diseases of implant and tooth-supporting tissues. Recently, the role of gene polymorphisms of immune response components in the relevant pathogenesis has been investigated. The present study was the first to evaluate the relationship between two known single nucleotide polymorphisms ...
Kadkhodazadeh M, Baghani Z, Ebadian AR, Kaghazchi Z, Amid R.   +4 more
europepmc   +4 more sources

Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health. [PDF]

J Periodontal Implant Sci, 2013
The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system plays a significant role in osteoclastogenesis, activation of osteoclasts, and regulation of bone resorption. This study aimed to evaluate the use of the salivary soluble RANKL (sRANKL)/OPG ratio as a diagnostic marker for periodontitis in ...
Tabari ZA, Azadmehr A, Tabrizi MA, Hamissi J, Ghaedi FB.   +4 more
europepmc   +4 more sources

Angiotensin II Induces Aortic Rupture and Dissection in Osteoprotegerin‐Deficient Mice

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background The biological mechanism of action for osteoprotegerin, a soluble decoy receptor for the receptor activator of nuclear factor‐kappa B ligand in the vascular structure, has not been elucidated.
Toshihiro Tsuruda, Atsushi Yamashita, Misa Otsu, Masanori Koide, Yuko Nakamichi, Yoko Sekita‐Hatakeyama, Kinta Hatakeyama, Taro Funamoto, Etsuo Chosa, Yujiro Asada, Nobuyuki Udagawa, Johji Kato, Kazuo Kitamura   +12 more
doaj   +1 more source

Exploring new pathways in endocrine-resistant breast cancer

Exploration of Targeted Anti-tumor Therapy, 2022
The most common breast cancer (BC) subtypes are hormone-dependent, being either estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), or both, and altogether comprise the luminal subtype.
Inês Soares de Pinho, Catarina Abreu, Inês Gomes, Sandra Casimiro, Teresa Raquel Pacheco, Rita Teixeira de Sousa, Luís Costa   +6 more
doaj   +1 more source

Effect of lipopolysaccharide derived from surabaya isolates of Actinobacillus actinomycetemcomitans on alveolar bone destruction [PDF]

Veterinary World, 2018
Background: Actinobacillus actinomycetemcomitans' lipopolysaccharide (LPS) has a high virulence factor. It interacts with serum protein through receptors on the epithelial cell surface, thereby increasing both interleukin (IL)-1β, and IL-6 which results ...
Rini Devijanti Ridwan, Sidarningsih, Tuti Kusumaningsih, Sherman Salim   +3 more
doaj   +1 more source

Receptor Activator of Nuclear Factor-κB Ligand Activates Nuclear Factor-κB in Osteoclast Precursors* [PDF]

Endocrinology, 2001
Receptor activator of nuclear factor-kappa B ligand [RANK ligand (RANK-L)] stimulates mature osteoclasts to resorb bone, a process associated with NF-kappa B activation. RANK-L also prompts macrophages to develop the osteoclast phenotype. Although NF-kappa B is essential for osteoclast differentiation, it is not known whether RANK-L activates this ...
S, Wei, S L, Teitelbaum, M W, Wang, F P, Ross   +3 more
openaire   +2 more sources